Top Tech Companies (1,916)
Don't see your company?
Create a company profile
At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm.
CBA Pharma manufactures, markets, licenses, and distributes drugs for medical oncology community.
ABOUT BRIGHTSEED Brightseed is a world leader in biosciences and artificial intelligence that illuminates nature to restore human health. Through our Forager® A.I., Brightseed helps companies gain the deepest insight into bioactives and their innovation potential. Forager accelerates bioactive discovery and biological validation from years to months – and is rapidly revealing new connections between nature and humanity. Brightseed partners with companies across the consumer health continuum to provide novel insights and science-backed health solutions. ABOUT BIOACTIVES Bioactives are small molecule compounds produced by plants, fungi, and microbes that grow in and adapt to environments that present a wide range of challenges to their survival. Bioactives also benefit the health of humans – they are the enlivening caffeine in tea, the powerful antioxidant lycopene in tomatoes, and they inform active ingredients in medicines like Taxol, Aspirin and Metformin, a first-line treatment for Type 2 diabetes, derived from the French lilac flower. Science has long known that bioactives are critical to human health, yet the vast majority remain unknown and uncharted. Brightseed’s A.I., Forager®, discovers bioactives in nature and maps them to human health outcomes at a rate and accuracy that was previously impossible.
What started as a small family business in 1988 has since evolved into a global market leader, providing orthopaedic and medical solutions that improve patient care around the world. Our story begins in Butler, NJ, where Mary and Randy Huebner founded Accurate Machine and Design, also known as Acumed. With only one machinist on staff, Acumed was contracted to engineer implant prototypes for some of the biggest names in the industry. After relocating to Oregon in 1991, we launched our first line of arthroscopy screws intended for ACL ligaments and haven’t looked back since. The successes of the Oregon Fixation Screw allowed Acumed to research, design, and manufacture the majority of our products while adding new lines each year. In 1999, Colson Associates, a division of The Marmon Group, purchased Acumed and provided the capital to purchase new equipment and a new facility to step up our production efforts. Currently Headquartered in Hillsboro, Oregon, with a global distribution network and offices worldwide Acumed is a multi-award-winning company, dedicated to innovative and quality medical device solutions. We are committed to the highest standards of manufacturing and proudly produce over 90% of our implants in the U.S. Throughout our history, Acumed has remained focused on the founders’ original vision of providing innovative solutions to meet the needs of the whole healthcare community, including hospitals, surgeons and patients.
At Biomason, our mission is to lead the global transition to planet-friendly construction. We are eliminating the need to emit carbon in cement production—curing the disease instead of treating the symptoms. Biomason biocement® will reduce 25% of carbon emission from the global concrete industry by 2030.
Vivex Biomedical is a biomedical company developing implant technology and stem cell therapies.
Vibalogics (now part of Recipharm) is a full-service CDMO offering process technical transfer, development, GMP manufacturing, testing and fill-finish services to innovators developing virotherapies. Through a comprehensive set of clinical- and commercial-enabling service offerings, we partner with our clients to support early-to-late stage success. Built on a foundation of robust industry-leading scientific expertise, quality systems and global regulatory compliance, we deliver manufactured products with a complementing customer service experience that is customer friendly, communication-forward, transparent and flexible. Service Offerings: GMP Cell Banking | GMP Viral Banking | Technical Transfer | Process & Analytical Development | GMP Drug Substance Manufacture | GMP Drug Product Manufacture | Formulation, Fill & Finish | Lot / Batch Release | Stability Studies Product Experience Includes: Live Viruses | Viral Vectors | Oncolytic Viruses | Gene Therapy | Vaccines | Adenovirus (Primate & Human) | Adeno-Associated (AAV) | Dengue | Herpes (HSV, Marek Disease, CMV) | Influenza (Flu) | Infectious Bursal Disease (IBDV) | Measles (Rubeola) | Newcastle Disease (NDV) | Poxviruses | Porcine Reproductive Respiratory Syndrome (PRRSV) | Respiratory-Syncitial Virus (RSV) | Vaccinia (VACV/MVA) | Vesicular Stomatitis Virus (VSV)
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are channeled through our locations in North America, Europe, the United Kingdom, and Asia. Together, we enable our clients to deliver the therapies that propel humanity forward. Cytel employs a range of data science tools from biostatistics to machine learning to help executives in the life-sciences to make confident decisions powered by data. We are probably best known for being leaders in the field of adaptive clinical trial design, a subset of trial design that uses interim looks to enhance the patient safety and commercial value of pharmaceutical products. We also have specialists in Bayesian statistics, real world evidence, artificial intelligence, health economics, and a number of other research fields to ensure that academic and scientific findings can have impact on industry quickly and seamlessly. www.cytel.com
Evoke Pharma develops therapeutics for the treatment of gastrointestinal diseases.
Penn Biotech Group (PBG) is a cross-disciplinary student run organization at the University of Pennsylvania.
We are Voyager Therapeutics, a pre-clinical stage biotech compelled by curiosity and powered by persistence. Voyagers are bold innovators who are energized in unlocking the full potential of AAV gene therapy employing our TRACER™ capsid discovery platform. Our resolve is to advance the field of AAV gene therapy, and through our innovative capsids, we are extending the reach and impact of our technology to help more patients in need. Recognizing that we can expand on the experience, innovation, and outcomes that propel our efforts by working together, we actively seek diverse views. If you’re someone who wants to make discoveries that change the landscape of medicine for patients, we want you on our team!
Beacon Biomedical is a biotech company, focuses on developing and commercializing waived tests for earlier cancer detection.
Carmot Therapeutics, Inc. is a clinical-stage company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative, patented drug discovery approach, Chemotype Evolution to explore novel frontiers of chemistry and biology. Using Chemotype Evolution, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular processing and characterization. Our disruptive levitation technology overcomes current technological limitations by providing a gentle, simple and label-free method of isolating specific cell populations. The LeviCell platform enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types, regardless of the starting cell number, viability, or sensitivity to processing.
Machine Learning for Drug Discovery. PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster. We've raised $26M from top investors, secured a $68M NIH partnership to prevent pandemics, and established a $260M partnership with Pfizer. We also launched and help lead the world's largest open-science initiative to find a COVID antiviral; COVID Moonshot.
Life Edit is a next-generation gene editing company dedicated to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable. Our platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. Life Edit has one of the world’s largest and most diverse arrays of novel RNA-guided nucleases and base editors that are active in mammalian cells. They were developed from a proprietary collection of non-pathogenic organisms, and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Our genome editing platform is derived from AgBiome’s proprietary collection of tens of thousands of microbes. We retain access to this growing microbial collection to mine for gene editing systems with uses in human therapeutics. Life Edit is an Elevatebio portfolio company. We are focused on strengthening our platform, developing a pipeline of gene therapies, and sharing our expertise through strategic partnerships.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.
Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.
Amnio Technology is a company based out of 22510 N 18TH DR, PHOENIX, Arizona, United States.
